Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial [Seeking Alpha]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Seeking Alpha
The trial showed improvement in pancreatic function, as measured by C-peptide response, following 24 weeks of treatment with AMX0035; worsening is typically expected with disease progression based on natural history studies of Wolfram syndrome. Longer-term data for all participants who have completed Week 36 and Week 48 assessments showed sustained improvement over time. Improvements or stabilization observed across all secondary endpoints, including measures of glycemic control, vision, and patient- and clinician-reported impressions of overall disease burden. AMX0035 was generally well-tolerated in all participants. Source: Press Release More on Amylyx Pharmaceuticals Amylyx Pharmaceuticals: Management Ambitiously Navigates Challenges Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript Seeking Alpha's Quant Rating on Amylyx Pharmaceuticals Historical earnings data for Amylyx Pharmaceuticals Financial information for Amylyx Pharmaceuticals Reco
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, up previously from $4.20.MarketBeat
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was given a new $4.00 price target on by analysts at Leerink Partners. They now have a "market perform" rating on the stock.MarketBeat
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Why Amylyx Pharmaceuticals Stock Was So Healthy This Week [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram SyndromeBusiness Wire
AMLX
Earnings
- 8/8/24 - Miss
AMLX
Analyst Actions
- 10/18/24 - HC Wainwright
AMLX
Sec Filings
- 10/25/24 - Form SC
- 10/17/24 - Form 8-K
- 10/2/24 - Form 4
- AMLX's page on the SEC website